Home - Products - Others - Other Targets - (D-Arg1,D-Phe5,D-Trp7·11)-Substance P

(D-Arg1,D-Phe5,D-Trp7·11)-Substance P

CAS No. ———

(D-Arg1,D-Phe5,D-Trp7·11)-Substance P( ——— )

Catalog No. M40445 CAS No. ———

(D-Arg1,D-Phe5,D-Trp7·11)-Substance P

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
25MG Get Quote Get Quote
50MG Get Quote Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    (D-Arg1,D-Phe5,D-Trp7·11)-Substance P
  • Note
    Research use only, not for human use.
  • Brief Description
    (D-Arg1,D-Phe5,D-Trp7·11)-Substance P
  • Description
    (D-Arg1,D-Phe5,D-Trp7·11)-Substance P
  • In Vitro
    ———
  • In Vivo
    ———
  • Synonyms
    ———
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    ———
  • Research Area
    ———
  • Indication
    ———

Chemical Information

  • CAS Number
    ———
  • Formula Weight
    ———
  • Molecular Formula
    ———
  • Purity
    >98% (HPLC)
  • Solubility
    ———
  • SMILES
    ———
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Europine

    Europine shows both antifungal and insect antifeedant activity.

  • [Ala1,?3,?11,?15]?-?...

    [Ala1,3,11,15]-Endothelin (TFA) is a highly selective for endothelin A (ETA) and endothelin B (ETB) receptor.[Ala1,?3,?11,?15]?-?Endothelin is a selective ETB endothelin receptor agonist (IC50 values are 0.33 and 2200 nM for displacing [125I]-ET-1 from ETB and ETA receptors respectively).

  • NNMTi

    NNMTi? is a substrate site-targeting, selective nicotinamide N-methyltransferase (NNMT) inhibitor (IC50 = 1.2 μM;?50 μM SAM, 100 μM NCA) that reduces 3T3-L1 lipogenesis (EC50 = 30μM) and adipocytes 1-methylnicotinamide level (EC50 = 2.3 μM) without affecting related methyltransferases & enzymes in the NAD+ salvage pathwayNNMTi treatment will rescue age-related deficits in muSC activity to promote superior regeneration post-injury in aging muscle.